Grace Therapeutics, Inc. (GRCE) Q4 2025 Earnings
GRCE·Reported February 12, 2026·Before market open
Diluted EPS came in at $-0.14 (+46.2% YoY), missed the $-0.09 consensus by $0.05.
Diluted EPS
$-0.14missed by $0.05
Consensus: $-0.09
Financial Snapshot
Trailing eight quarters through Q4 2025
Q4 2025 Earnings FAQ
Common questions about Grace Therapeutics, Inc.'s Q4 2025 earnings report.
Grace Therapeutics, Inc. (GRCE) reported Q4 2025 earnings on February 12, 2026 before market open.
Grace Therapeutics, Inc. reported diluted EPS of $-0.14 for Q4 2025.
EPS missed the consensus estimate of $-0.09 by $0.05.
Compared to the same quarter a year prior, diluted EPS grew 46.2% from $-0.26.
You can read the 8-K earnings release (0001140361-26-004927) and the 10-Q periodic report (0001140361-26-004924) directly on SEC EDGAR. The filing index links above go to sec.gov.